精彩内容11月26日,CDE官网显示, 广东东阳光药业|宜昌东阳光长江药业的苯磺酸氨氯地平颗粒以化药2.2类新药报产在审。米内网数据显示,高血压化药在2023年中国三大终端六大市场(统计范围见文末)销售规模超过600亿元。苯磺酸氨氯地平用于高血压治疗,可单独应用或与其他抗高血压药物联合使用;用于冠心病的治疗,如慢性稳定性型心绞痛、血管痉挛型心绞痛。近年中国三大终端六大市场高血压化药销售情况(单位:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.